AVIR Atea Pharmaceuticals
- 3.960
- -0.080-1.98%
- 3.840
- -0.120-3.03%
Atea Pharmaceuticals News
Atea Pharmaceuticals | 10-Q: Quarterly report
Atea Pharmaceuticals Q1 2024 GAAP EPS $(0.75) Misses $(0.61) Estimate
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 74.42 percent decrease over losses
Atea Pharmaceuticals 1Q Loss/Shr 75c >AVIR
Atea Pharmaceuticals 1Q Loss/Shr 75c >AVIR
Press Release: Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expect
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antivi
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
Atea Pharmaceuticals: Balancing Promising Prospects With Clinical and Regulatory Risks
Earnings Call Summary | Atea Pharmaceuticals(AVIR.US) Q4 2023 Earnings Conference
The following is a summary of the Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript:Financial Performance:Atea Pharmaceuticals reported an increase in R&D expenses for Q4 and full yea
Q4 2023 Atea Pharmaceuticals Inc Earnings Call
Recap: Atea Pharmaceuticals Q4 Earnings
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsAtea Pharmaceuticals b
Atea Pharmaceuticals GAAP EPS of -$0.47 Beats by $0.03
Press Release: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. • Golden Ocean Group (NASDAQ:GOGL) is likely to report
Atea Pharmaceuticals Earnings Preview
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Wednesday, 2024-02-28. Here's what investors need to know before the announcement.Analysts estimate that Atea
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral th
Atea Pharmaceuticals(AVIR.US) Officer Sells US$60,914.75 in Common Stocks
$Atea Pharmaceuticals(AVIR.US)$ Officer Corcoran Andrea sold 15,843 shares of Common Stocks on Feb 1, 2024 at an average price of $3.8449 for a total value of $60,914.75.Source: Announcement What is s
Atea Pharmaceuticals(AVIR.US) Officer Sells US$47,904.19 in Common Stocks
$Atea Pharmaceuticals(AVIR.US)$ Officer Foster Wayne sold 12,477 shares of Common Stocks on Feb 1, 2024 at an average price of $3.8394 for a total value of $47,904.19.Source: Announcement What is stat
Atea Pharmaceuticals(AVIR.US) Officer Sells US$218.82K in Common Stocks
$Atea Pharmaceuticals(AVIR.US)$ Officer Sommadossi Jean-Pierre sold 56,910 shares of Common Stocks on Feb 1, 2024 at an average price of $3.845 for a total value of $218.82K.Source: Announcement What
Atea Pharmaceuticals(AVIR.US) Officer Sells US$60,963.02 in Common Stocks
$Atea Pharmaceuticals(AVIR.US)$ Officer Horga Maria Arantxa sold 15,870 shares of Common Stocks on Feb 1, 2024 at an average price of $3.8414 for a total value of $60,963.02.Source: Announcement What
Analysis
Price Target
No Data
